Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

The impact of human papillomavirus vaccination on cervical cancer prevention efforts.

Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N, Solomon D.

Gynecol Oncol. 2009 Aug;114(2):360-4. doi: 10.1016/j.ygyno.2009.04.005. Epub 2009 May 1. Review.

2.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

4.

What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?

Huh W, Einstein MH, Herzog TJ, Franco EL.

Gynecol Oncol. 2010 Jun;117(3):481-5. doi: 10.1016/j.ygyno.2010.01.037. Epub 2010 Apr 24. Review.

PMID:
20417957
5.
6.

Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.

Society of Gynecologic Oncologists Education Resource Panel Writing group, Collins Y, Einstein MH, Gostout BS, Herzog TJ, Massad LS, Rader JS, Wright J.

Gynecol Oncol. 2006 Sep;102(3):552-62. Review.

PMID:
16979432
7.

The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.

Sigurdsson K, Sigvaldason H, Gudmundsdottir T, Sigurdsson R, Briem H.

Acta Obstet Gynecol Scand. 2009;88(1):27-35. doi: 10.1080/00016340802566770.

PMID:
19031282
8.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
9.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

10.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; HPV PATRICIA Study Group.

Lancet Oncol. 2012 Jan;13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075171
11.

Age-appropriate use of human papillomavirus vaccines in the U.S.

Castle PE, Fetterman B, Akhtar I, Husain M, Gold MA, Guido R, Glass AG, Kinney W.

Gynecol Oncol. 2009 Aug;114(2):365-9. doi: 10.1016/j.ygyno.2009.04.035. Epub 2009 May 22. Review.

12.

Cervical cancer: screening and prevention.

Behtash N, Mehrdad N.

Asian Pac J Cancer Prev. 2006 Oct-Dec;7(4):683-6. Review.

13.

Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.

Cuzick J, Castañón A, Sasieni P.

Br J Cancer. 2010 Mar 2;102(5):933-9. doi: 10.1038/sj.bjc.6605528. Epub 2010 Jan 26.

14.

Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age.

Harper DM.

Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S11-7. doi: 10.1016/j.ygyno.2008.06.029. Epub 2008 Jul 22.

PMID:
18649932
15.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, Kitchener H, Fong KL, Bouchard C, Money DM, Ilancheran A, Cruickshank ME, Levin MJ, Chatterjee A, Stapleton JT, Martens M, Quint W, David MP, Meric D, Hardt K, Descamps D, Geeraerts B, Struyf F, Dubin G; VIVIANE Study Group.

Lancet. 2014 Dec 20;384(9961):2213-27. doi: 10.1016/S0140-6736(14)60920-X. Epub 2014 Sep 1.

PMID:
25189358
16.

How does public policy impact cervical screening and vaccination strategies?

Herzog TJ, Huh WK, Einstein MH.

Gynecol Oncol. 2010 Nov;119(2):175-80. doi: 10.1016/j.ygyno.2010.08.021. Review.

17.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
18.

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P.

Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.

20.

Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.

Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ.

Lancet Oncol. 2012 Jan;13(1):78-88. doi: 10.1016/S1470-2045(11)70296-0. Epub 2011 Dec 14.

PMID:
22177579

Supplemental Content

Support Center